MTP17-01: Evidence-based supportive management in lung cancer  by Van Meerbeeck, Jan P.
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS282
indicate that single-agent chemotherapy could be the preferred option 
in the treatment of PS 2 patients, with carboplatin-based or low-dose 
cisplatin-based doublets representing alternative options .To date 
randomised trial in USA (carboplatin+ gemcitabine vs gemcitabine) 
and in Italy (cisplatin+gemcitabine vs gemcitabine) are ongoing. In 
the near future, the role of targeted agents with better safety proﬁle 
than chemotherapy as the EGFR-TKI erlotinib, has to be explored in 
the ﬁrst-line treatment of advanced NSCLC PS2 patients . Non small 
cell lung cancer (NSCLC) may be considered typical of advanced 
age. More than 50% of lung cancer patients are diagnosed over the 
age of 65 and about 30% over the age of 70. More than two-thirds of 
patients dying of lung cancer in the United States are over 65 years old. 
Elderly patients tolerate chemotherapy poorly because of comorbid-
ity and organ failure. Prospective phase II trials have demonstrated 
suitable toxicity proﬁle and good antitumor activity for single agent 
chemotherapy with vinorelbine, gemcitabine and taxanes in the treat-
ment of advanced NSCLC elderly patients. Vinorelbine, in a phase 
III randomized trial named ELVIS (Elderly Lung Cancer Vinorelbine 
Italian Study), compared to best supportive care, has proven to improve 
survival and quality of life of advanced NSCLC patients. In order to 
improve results obtained with monochemotherapy, the development of 
non cisplatin-based combinations is an interesting issue in the treatment 
of advanced NSCLC elderly patients. In fact the possibility of having 
active and well-tolerated chemotherapy while preserving patient quality 
of life is more attractive in the elderly. The most studied non platin-
based regimen is the combination of gemcitabine plus vinorelbine, 
resulted active and well-tolerated in several phase II trials. However, 
a large phase III randomized trial (MILES-Multicenter Italian Lung 
cancer in the Elderly Study), enrolling about 700 patients, showed that 
polychemotherapy with gemcitabine and vinorelbine does not improve 
any outcome (response rate, time to progression, survival or quality 
of life) as compared to single agent chemotherapy with vinorelbine or 
gemcitabine. In clinical practice, single agent chemotherapy should 
remain the standard treatment. Feasibility of cisplatin-based polyche-
motherapy remains an open issue and has been recently addressed by 
some retrospective analyses of randomized trials without age limits, 
suggesting that advanced age alone should not preclude aggressive 
cisplatin-based treatment to ﬁt NSCLC elderly patients. The evidences 
from these analyses could however suffer from selection bias, because 
their target population may not be representative of the whole elderly 
population but only of a small subgroup thought to be eligible for 
aggressive treatments by investigators. Prospective clinical trials with 
inclusion criteria selective for elderly population are to be considered 
the unique tool for investigating cisplatin-based chemotherapy in this 
clinical setting. More recently some prospective phase II trials have ex-
plored innovative schedules of cisplatin delivering that could be more 
suitable to elderly population . 
Among new biologic agents, the Epidermal Growth Factor Receptor ty-
rosine-kinase inhibitor erlotinib, characterized by a favourable toxicity 
proﬁle, potentially suitable to elderly population, is being investigated. 
Erlotinib has been tested as ﬁrst-line treatment in unselected elderly 
patients showing good tolerability and activity with 11% response rate 
and a median survival of 10.5 months. Among antiangigenetic agents 
ZD1271 seems be of interest in the elderly. Drugs with multiple target 
are the new frontiers of biologic therapy. ZD6474, a small molecule 
that inhibits VEGF and EGFR, and sorafenib , with VEGF , PDGF and 
c-kit as target, merit to be investigated in elderly NSCLC patients. 
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Staging of the intrathoracic mediastinal and pulmonary lymph nodes is 
one of the most important problems in the treatment of non-small cell 
lung cancer. The map of the mediastinal and pulmonary lymph nodes 
proposed by Clifton F. Mountain and Carolyn M. Dresler gained wide 
acceptance and has become a standard of staging. However, it has some 
shortcomings of clarity in the description of localization of speciﬁc 
nodal stations. In our opinion, some modiﬁcations of this map are 
necessary. Based on our experience with extended mediastinoscopy and 
the new procedure, transcervical extended mediastinal lympadenec-
tomy, the main changes we propose are: 1) the left innominate vein as 
the anatomic separation between nodal stations 1 and 2; 2) the merging 
of station 2 and 4 in a single right and left paratracheal station; 3) the 
shift of the midline to the left paratracheal margin; 4) the tracheobron-
chial angles as the landmark between stations 4 and 10 bilaterally; 5) 
the separation of three nodal groups in the subcarinal area: subcarinal 
(number 7), peribronchial (number 10R and 10L), and periesophageal 
(number 8); 6) the merging of station 5 and station 6 nodes in a single 
station with the following landmarks: medial border: the midline, 
lateral border, the descending aorta and upper border: the left innomi-
nate vein and lower border: the lower margin of the left pulmonary 
artery; and 7) the deﬁnition of station 3A nodes as those in front of the 
superior vena cava.
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Introduction
Despite improvements in early diagnosis and treatment, the vast major-
ity-85%- of patients with lung cancer will ultimately die from their 
disease and most of them within 1 year of diagnosis. Physicians caring 
for patients with lung cancer should hence be aware of the prevailing 
symptoms in the advanced stage and acquire the expertise to cope with 
these. 
The British Medical Research Council reported on patient’s selfreport-
ed symptoms were similar in NSCLC and SCLC and came from a vari-
ety of domains: psychological (worrying and anxious feelings), general 
(tiredness, lack of energy, lack of appetite and difﬁculty sleeping) and 
chest symptoms (shortness of breath and cough) [Hopwood 1995]. The 
symptoms most frequently reported as severe were: decreased sexual 
interest, lack of energy and dyspnea.The number of symptoms reported 
was on average 17.4 for SCLC and 14.3 for NSCLC and increased with 
worsening performance status. An effect of gender was not clear. In the 
course of illness, most symptoms tend to recur or increase in number 
and severity. 
This article will focus on the evidence-based comprehensive manage-
ment of 4 symptoms speciﬁc to patients with lung cancer: dyspnea, 
cough, hemoptysis, anorexia/cachexia and fatigue. This review 
deliberately excludes chemo- and radiotherapy, invasive interventions 
and the management of pain, as these are dealt with in a number of 
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excellent systematic reviews and guidelines that have been published in 
text books and journals [Boyar 2005, Hoskin 2005, Lester 2006, Muers 
2004, NCCAC 2005, Potter 2004, Stinnet 2007, Ung 2006]. 
Dyspnea
Dyspnea in lung cancer is often multifactorial and can be related either 
to cancer, its therapy or comorbid conditions [Thomas 2002]. Its patho-
physiology is not completely understood. Dyspnea can be objectivated 
by either the Borg score or a 0-10 point Visual Analog Scale (VAS). 
A relation between dyspnea and oxygen tension is not straightforward. 
Whereas supplemental oxygen can be helpful if patients are hypox-
emic, this is not necessarily the case. In a randomized controlled trial, 
dyspneic patients with advanced cancer were treated with either supple-
mental oxygen or air [Philip 2006]. On average, patients improved 
symptomatically with both air and oxygen, and there were no signiﬁ-
cant differences between the treatments. A subgroup of 17 hypoxic 
patients overall did not demonstrate a signiﬁcant difference between 
air and oxygen, despite having improved oxygen saturations when 
administered oxygen. Other randomized trials have similarly shown no 
incremental beneﬁt of supplemental oxygen in cancer patients with ei-
ther dyspnea at exercise or at rest [Bruera 1993, Booth 1996]. Booth et 
al. measured VAS at baseline and after inhalation of supplemental oxy-
gen or air in a cross-over design in 38 cancer patients. VAS dropped as 
compared to baseline, with no difference between both administrations 
and regardless of their sequence. Moreover, the correlation between 
baseline oxygen saturation and change of VAS with oxygen was low 
(r=0.13), suggesting that other mechanisms are involved. One of these 
is stimulation of the soft palate or the second root of the trigeminal 
nerve with cold air [Thomas 2002]. Patients can hence consider using a 
fan to blow cool air on their face when they are dyspneic.
Whenever dyspnea is present, it is worth looking whether there are 
any reversible underlying causes. Symptomatic pleural or pericardial 
effusion can be drained by thora-/pericardiocentesis and controlled by 
pleuro-/pericardiodesis, central airway obstruction can be managed 
by (laser-)debulking, cryotherapy, or stenting. Anticoagulants might 
prevent further pulmonary embolism. Chemotherapy and thoracic 
radiotherapy have shown to improve dyspnea. 
Opioids are by far the most effective pharmacologic agent for the 
improvement of dyspnea. Its mechanism of action is explained by 
the presence of opioid receptors in the central and peripheral nervous 
system. Several randomised trials have shown improvement in dyspnea 
with morphine. The evidence was reviewed by Jennings et al [Jen-
nings 2002]. Current recommendations advocate in opioid-naive pts 
with mild dyspnoea (VAS < 5) the use of either hydrocodone 5 mg 
or codeine 30 mg orally q4h with a breakthrough equivalent dose prn 
every 2h [Thomas 2002]. In opioid-naive pts with severe dyspnoea 
(VAS >5), morphine sulphate 5 mg or oxycodone 5 mg or hydromor-
phone 1 mg orally q 4h is given with a breakthrough equivalent dose as 
needed q 2h. The dose is titrated in increments of 50% q 24h as needed; 
in COPD patients, doses and increments are started at 50% doses. If 
patients are already opioid tolerant, an increase in their baseline opioid 
dose by 25-50% is recommended.
Opioid receptors have also been described in the tracheobronchial tree, 
suggesting a possible role for inhaled opioids. A number of small stud-
ies suggest a possible beneﬁt from nebulized opioids, either morphine 
or fentanyl. However, in COPD, nebulized opioids do not appear to 
play a role in the relief of dyspnea. In one randomized trial, nebulized 
morphine offered dyspnea relief similar to that of subcutaneous mor-
phine [Bruera 2006]. In their systematic review, Jennings et al conclude 
that there are currently insufﬁcient data to conclude whether nebulised 
opioids are effective [Jennings, 2002]. 
Although patients with dyspnea appear anxious, anxiety is not the 
only etiology of breathlessness, and the diagnosis should be exclusive. 
A number of randomized trials in healthy and COPD patients with 
dyspnea have failed to shown a beneﬁt of anxiolytics for dyspnea. 
Because of this, there is no evidence for a single agent therapy with 
benzodiazepines for ﬁrst-line therapy of dyspnea, unless there is a 
substantial component of anxiety, in which case they can be associated 
with opioids.
There is strong evidence to support behavioral and nursing interven-
tions for dyspnea [Bredin 1999]. Relaxation, breathing techniques and 
psychosocial support can affect the cognitive and emotional compo-
nents of dyspnea. These interventions are compelling, require specialty 
training and are not widely available.
Around 90% of lung cancer patients experience dyspna in the last 
month of their life. Occasionally, they do not obtain relief with any of 
the modalities reviewed. For uncontrolled dyspnea in poor-prognosis 
advanced stage patients, terminal sedation with opioids and sedatives is 
to be considered [Von Roenn 2004].
Cough & hemoptysis
Cough can be related to the tumor itself or its treatment and might be 
relieved by chemo- and radiotherapy. As many lung cancer patients 
have comorbid COPD, a bronchodilator therapy might relieve some 
of the cough. Steroids might be appropriate if lymphangitic spread is 
suspected. Opioids are the most effective cough suppressant by their 
action on the central airways. In opioid naïve patients, codeine and 
oxycodone is the most used opioid, although there are no prospective 
randomized studies. Long acting drugs may be appropriate when the 
patient requires >3-4 doses a day. The role of other central non-opi-
oid cough suppressants is unclear. Excess mucus and secretions can 
be moistened by saline inhalations for better expectoration. Terminal 
patients are often too weak to have an adequate cough reﬂex, resulting 
in noisy breathing from excess secretions in the large airways. Anticho-
linergics such as scopolamine can be helpful to dry up secretions[Von 
Roenn 2004].
Hemoptysis is most commonly observed in endobronchial tumor and is 
more common in NSCLC. Bloood expectorated from a cancer is usu-
ally fresh due to its bronchial arterial source. Patients with pre-existing 
pulmonary disease may usually distinguish it from the dark staining of 
sputum associated with an exacerbation of COPD. Two drugs are oftenn 
used in this situation, although the evidence for their efﬁcacy is weak. 
Tranexamic acid works by inhibiting the breakdown of ﬁbrin clots, by 
blocking the binding of plasminogen and plasmin: itb is given orally at 
adose of 1 g four times daily. A randomized double blinded placebo con-
trolled trial in using tranexamic acid in hemoptysis patients could not 
demonstrate a shortening in the days of hemoptysis [Tscheikuna 2002].
Ethamsylate works rather through increasing capillary vascular wall 
resitance and platelet adhesiveness. This agent is also given orally at 
a dose of 500 mg four times daily. There are no published randomized 
trials of the use of this agent for hemoptysis. Uncontrolled hemop-
tyis or patients at risk of major bleeding, may be readily controlled 
with local radiotherapy either by external beam or endobronchially. 
Hemoptysis from parenchymal origin can be treated by radiotherapy if 
a deﬁnite segment of the lung can be identiﬁed. Selected patients might 
sometimes also proﬁt from arterial embolization.
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Cancer related anorexia/cachexia syndrome (CACS)
Anorexia is the loss of desire to eat. Cachexia is manifested as weight 
loss involving both adipose tissue and skeletal muscle. CACS is com-
mon in advanced lung cancer patients and bears a poor prognosis. 
Wasting is not due to malnutrition, which preferentially depletes lipids 
from adipose tissue, but involves a complex disruption of several sys-
tems that also leads to anemia, insulin resistance, immunosuppression, 
and activation of an acute-phase response. A recent study by Acharyya 
et al. shows that soluble factors released from tumors or immune ef-
fector cells and implicated in cachexia can lead to a speciﬁc decrease 
in the levels of the myosin heavy chain, a muscle contractile protein 
[Acharyya 2004, Chamberlain 2004].
Because of the underlying metabolic changes, sufﬁcient energy intake 
cannot compensate for the increased energy expenditure. Hence, enteral 
and total parenteral nutrition do not play a role in treating anorexia 
unless there is an anatomic etiology. Although nutritional counsel-
ing might increase food intake, there is no evidence that it improves 
nutritional status. Exercise is a non-pharmacologic intervention that 
has been shown to increase lean body mass and/or muscle strenght in 
patients with during breast cancer therapy and stemcell transplantation. 
Studies in lung cancer are however lacking. 
Pharmacologic management of CACS includes orexigenic -progesta-
gens, cannabinoids, corticosteroids- antimetabolic and anabolic agents. 
Medroxyprogesteron acetate (MPA) is the most well-studied drug 
and has been shown to stimulate increased food intake signiﬁcantly 
and to reverse fat loss concomitantly [Simons 1998]. The observed 
weight gain appears to be mainly because of increased adipose tissue 
rather than lean body mass [Loprinzi 1993]. A Cochrane meta-analysis 
showed a beneﬁt of MPA compared with placebo, particularly with 
regard to appetite improvement and weight gain in cancer patients [Be-
renstein 2005]. Analysis of quality of life was hampered by clinical and 
statistical heterogeneity. There was insufﬁcient information to deﬁne 
the optimal dose of MPA. A major concern about progestational agents 
is the increased potential for thrombotic events, that is dose related. 
Patients with lung cancer have a very high rate of thromboembolic 
disease and the beneﬁt of MPA should be balanced in the individual 
patient against this risk. Other toxicities included impotence in 26% of 
men, adding to the decreased sex interest already present in a sizable 
number of patients [Hopwood 1995].
Cannabinoids reputedly stimulate appetite, both historically and in 
recent studies of human volunteers and AIDS patients. Two randomized 
studies have investigated the role of cannabinoids in CACS versus pla-
cebo, MPA and a combination of cannabinoids and MPA [Jatoi 2002, 
Strasser 2006]. Cannabinoids did not improve patients’ appetite, QOL 
or survival as compared to placebo and was inferior to MPA. Cannabi-
noids hence do not have a clear role for CACS. 
Corticosteroids clearly improve appetite usually for a short time with-
out associated weight gain. Randomized comparisons with MPA are 
lacking. In addition long term administration results in proximal muscle 
weakness and central adiposity. 
Eicosapentaenoic acid (EPA), an α-3-omega fatty acid, has been pro-
posed to have speciﬁc anticachectic effects. Several randomized studies 
have investigated the role of EPA in CACS versus placebo, MPA and a 
combination of EPA and MPA [Bruera 2003]. Cannabinoids did not im-
prove patients’ appetite, weight or survival as compared to placebo and 
was inferior to MPA. EPA hence does not have a clear role for CACS. 
Anabolic agents have not been well studied in cancer patients. Several 
small studies suggest a beneﬁt of nadrolone in patients with lung 
cancer. Randomized comparisons with MPA or corticosteroids are 
lacking. Extracellular adenosine 5-triphosphate (ATP) is involved 
in the regulation of a variety of biologic processes, including neuro-
transmission, muscle contraction, and liver glucose metabolism, via 
purinergic receptors. In nonrandomized studies involving patients with 
different tumor types including NSCLC, ATP infusion appeared to 
inhibit loss of weight and deterioration of QOL and performance status. 
Agteresch et al. demonstrated in a randomized trial in 58 patients with 
advanced NSCLC, that ATP infusion had beneﬁcial effects on weight, 
muscle strength, and QOL [Agteresch 2000]. Conﬁrmatory evidence is 
awaited.
Cancer related fatigue (CRF)
Cancer-related fatigue is a complex, multidimensional problem that 
results from the cancer itself, the therapies used to treat it and coexist-
ing physical and psychological conditions. Fatigue should be assessed 
in every cancer patient at regular intervals using either a Likert scale 
or a 0-10 point VAS. There are a number of potentially reversible 
causes of CRF that can be corrected or minimized: anemia, metabolic 
or electrolyte disturbances, sleeping disorders, depression, side -effects 
of medication. The most-well studied pharmacologic agent in CRF is 
methylphenidate, which is a mild central nervous system stimulant. Its 
mechanism of action is blockage of presynaptic dopamine reuptake. In 
patients with cancer, methylphenidate has been used to manage opioid-
induced sedation, cognitive failure associated with brain tumors, and 
depression. Methylphenidate is usually administered twice a day, at 
breakfast and lunch, in order to minimize insomnia. However, because 
of its rapid onset of action and short half-life, methylphenidate may 
be effective in relieving fatigue when taken on an as-needed basis 
(patient-controlled) throughout the day. This ﬂexible administration 
regimen may signiﬁcantly improve the patient’s quality of life. After 
a promising phase 2 trial, Bruera et al conducted a randomized trial in 
112 patients using 5 mg of methylphenidate or placebo every 2 hours 
as needed to a maximum of 4 capsules a day [Bruera 2006]. Fatigue 
intensity improved signiﬁcantly on day 8 in both the methylphenidate 
and placebo groups. However, there was no signiﬁcant difference in 
fatigue improvement between groups, as measured with questionnaires 
at day 8. Based on these data, the role of pharmacologic intervention in 
CRF is unclear and warrant additional placebo-controlled trials.
Conclusion
Lung cancer is a common malignancy with a high attrition rate and a 
high symptom burden not only in the end stages of disease but also in 
patients with newly diagnosed cancer. Many of these symptoms are 
complex and multifactorial. Comprehensive symptom management 
must begin at the time of diagnosis and continue throughout the course 
of the disease. Patients with advanced stage disease and limited life 
expectancy have the right for minimal suffering and optimal QOL. 
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Increasing understanding of the molecular mechanisms underlying 
tumor growth, progression, and metastasis over the past decade has 
identiﬁed promising targets for the treatment of tumors, including lung 
cancer. In particular targets in the PI3Kinase-Akt survival pathway 
and the ras-raf-ERK proliferative pathway are of increasing relevance. 
